Literature DB >> 3282444

Immunohistochemical characterization of a set of monoclonal antibodies to human neuron-specific enolase.

B Seshi1, L True, D Carter, J Rosai.   

Abstract

This paper describes the immunohistochemical staining properties of four monoclonal antibodies (MAbs) (CF, EB, AD, and KB) which had been previously shown to be specific for purified neuron-specific enolase (NSE) by a solid-phase radioimmunoassay. In this study, the authors immunostained a spectrum of normal and neoplastic neuronal, "neuroendocrine," and nonneuronal tissues fixed in formalin and embedded in paraffin. Positivity was generally restricted to normal neuronal structures and neuronal tumors, including adrenal neuroblastoma, ganglioneuroblastoma, olfactory neuroblastoma, pheochromocytoma, carotid body paraganglioma, duodenal gangliocytic paraganglioma, and teratoma with neuroepithelial components. Three staining patterns of the normal or neoplastic neuronal structures were observed: two MAbs (CF and EB) stained predominantly the nerve fibers (axoplasm); one (AD) stained predominantly the cell bodies (perikaryon); and one (KB) stained both the axoplasm and the perikaryon. "Neuroendocrine" tumors such as pulmonary small cell carcinoma, pancreatic islet cell tumor, thyroid medullary carcinoma, and carcinoid tumors from various locations showed a variable staining pattern. Tumor cells undergoing mitotic division were usually positive regardless of type. Normal structures other than neuronal or "neuroendocrine," including normal glial cells, were negative. The authors also studied a range of glial cell tumors with MAbs CF and AD as well as with Dako polyclonal antiserum to NSE. The results showed that CF stained the axonal fibers in the normal white matter surrounding these tumors; it did not stain the tumor cells or the perikarya of neurons in the surrounding normal gray matter. AD stained the glioma cells as well as the perikarya and dendrites of neurons in the surrounding normal gray matter; it did not stain the axonal fibers in the surrounding normal white matter. By contrast, the polyclonal antiserum stained all of these structures. The high degree of staining specificity of the MAbs should prove them to be valuable in immunohistochemical diagnosis of tumors as well as in further understanding the role of NSE in neuronal differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282444      PMCID: PMC1880593     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells.

Authors:  D Schmechel; P J Marangos; M Brightman
Journal:  Nature       Date:  1978 Dec 21-28       Impact factor: 49.962

2.  Monoclonal antibodies to human neuron-specific enolase reveal heterogeneity of the enzyme in neurons of the central nervous system.

Authors:  M J Frikke; B Seshi; C E Bell
Journal:  Brain Res       Date:  1987-08-11       Impact factor: 3.252

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Nerve-specific enolase and creatine phosphokinase in axonal transport: soluble proteins and the axoplasmic matrix.

Authors:  S T Brady; R J Lasek
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

Review 5.  The neurobiology of the brain enolases.

Authors:  P J Marangos; D Schmechel
Journal:  Essays Neurochem Neuropharmacol       Date:  1980

Review 6.  The APUD cell concept and its implications in pathology.

Authors:  A G Pearse
Journal:  Pathol Annu       Date:  1974

7.  Neuron-specific enolase is produced by neuroendocrine tumours.

Authors:  F J Tapia; J M Polak; A J Barbosa; S R Bloom; P J Marangos; C Dermody; A G Pearse
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

8.  Immunoassay of three enolase isozymes in human serum and in blood cells.

Authors:  K Kato; R Asai; A Shimizu; F Suzuki; Y Ariyoshi
Journal:  Clin Chim Acta       Date:  1983-02-07       Impact factor: 3.786

9.  Posttranslational processing of alpha-tubulin during axoplasmic transport in CNS axons.

Authors:  B A Brown; R A Nixon; C A Marotta
Journal:  J Cell Biol       Date:  1982-07       Impact factor: 10.539

10.  Posttranslational modification of a neurofilament protein during axoplasmic transport: implications for regional specialization of CNS axons.

Authors:  R A Nixon; B A Brown; C A Marotta
Journal:  J Cell Biol       Date:  1982-07       Impact factor: 10.539

View more
  6 in total

1.  Immunohistochemical demonstration of neurone specific enolase in bone marrow infiltrated by neuroblastoma.

Authors:  J M Caillaud; F Martinez-Madrigal; O Hartmann; C Carlu
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 2.  Duodenal gangliocytic paraganglioma. Report of a case and review of the literature.

Authors:  M Barbareschi; B Frigo; D Aldovini; E Leonardi; S Cristina; M Falleni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 3.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

4.  Immunohistochemistry of neurone specific enolase with gamma subunit specific anti-peptide monoclonal antibodies.

Authors:  G I Murray; M E Duncan; W T Melvin; J E Fothergill
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

Review 5.  The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.

Authors:  Giuseppe Pelosi; William D Travis
Journal:  Pathologica       Date:  2021-10

6.  Detection and organ-specific ablation of neuroendocrine cells by synaptophysin locus-based BAC cassette in transgenic mice.

Authors:  Chieh-Yang Cheng; Zongxiang Zhou; Alexander Yu Nikitin
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.